{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T03:46:57Z","timestamp":1784692017939,"version":"3.55.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,7,15]],"date-time":"2017-07-15T00:00:00Z","timestamp":1500076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","worldneurosurgery.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["World Neurosurgery"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.wneu.2017.07.036","type":"journal-article","created":{"date-parts":[[2017,7,16]],"date-time":"2017-07-16T03:00:19Z","timestamp":1500174019000},"page":"653-660","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Population Characteristics and Progressive Disability in Neurofibromatosis Type 2"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3573-6790","authenticated-orcid":false,"given":"Kensho","family":"Iwatate","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Iwatate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masazumi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Sakuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.wneu.2017.07.036_bib1","first-page":"172","article-title":"National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, MD, July 13-15, 1987","volume":"1","year":"1988","journal-title":"Neurofibromatosis"},{"key":"10.1016\/j.wneu.2017.07.036_bib2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/363515a0","article-title":"Alteration in a new gene encoding a putative membrane-organizing protein causes neurofibromatosis type 2","volume":"363","author":"Rouleau","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.wneu.2017.07.036_bib3","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","article-title":"A\u00a0novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor","volume":"72","author":"Trofatter","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.wneu.2017.07.036_bib4","first-page":"603","article-title":"A\u00a0clinical study of type 2 neurofibromatosis","volume":"84","author":"Evans","year":"1992","journal-title":"Q\u00a0J Med"},{"key":"10.1016\/j.wneu.2017.07.036_bib5","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3171\/jns.2003.99.3.0480","article-title":"Age at symptom onset and long-term survival in patients with neurofibromatosis Type 2","volume":"99","author":"Otsuka","year":"2003","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2017.07.036_bib6","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/neuonc\/nov200","article-title":"Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis","volume":"18","author":"Blakeley","year":"2016","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2017.07.036_bib7","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3171\/jns.2005.102.4.0643","article-title":"Resection of large vestibular schwannomas: facial nerve preservation in the context of surgical approach and patient-assessed outcome","volume":"102","author":"Anderson","year":"2005","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2017.07.036_bib8","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.otohns.2006.10.009","article-title":"Facial nerve function after translabyrinthine vestibular schwannoma surgery","volume":"136","author":"Brackmann","year":"2007","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.wneu.2017.07.036_bib9","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00129492-200501000-00016","article-title":"Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought","volume":"26","author":"Evans","year":"2005","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.wneu.2017.07.036_bib10","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1046\/j.1365-2273.1996.00816.x","article-title":"Factors which influence the facial nerve outcome in vestibular schwannoma surgery","volume":"21","author":"Grey","year":"1996","journal-title":"Clin Otolaryngol Allied Sci"},{"key":"10.1016\/j.wneu.2017.07.036_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000156905","article-title":"Microsurgery management of vestibular schwannomas in neurofibromatosis type 2: indications and results","volume":"21","author":"Samii","year":"2008","journal-title":"Prog Neurol Surg"},{"key":"10.1016\/j.wneu.2017.07.036_bib12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1086\/342716","article-title":"Predictors of the risk of mortality in neurofibromatosis 2","volume":"71","author":"Baser","year":"2002","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.wneu.2017.07.036_bib13","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/jmedgenet-2015-103290","article-title":"Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients","volume":"52","author":"Hexter","year":"2015","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.wneu.2017.07.036_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/02688697.2014.952266","article-title":"Causes of mortality in neurofibromatosis type 2","volume":"29","author":"Aboukais","year":"2015","journal-title":"Br J Neurosurg"},{"key":"10.1016\/j.wneu.2017.07.036_bib15","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1177\/0194599815573002","article-title":"Quality of life (QoL) assessment in patients with neurofibromatosis Type 2 (NF2)","volume":"153","author":"Cosetti","year":"2015","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.wneu.2017.07.036_bib16","first-page":"963","article-title":"Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2","volume":"261","author":"Ferner","year":"2014","journal-title":"J\u00a0Neurol"},{"key":"10.1016\/j.wneu.2017.07.036_bib17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1055\/s-0032-1301396","article-title":"The NFTI-QOL: a disease-specific quality of life questionnaire for neurofibromatosis 2","volume":"73","author":"Hornigold","year":"2012","journal-title":"J\u00a0Neurol Surg B Skull Base"},{"key":"10.1016\/j.wneu.2017.07.036_bib18","doi-asserted-by":"crossref","first-page":"5032","DOI":"10.1158\/1078-0432.CCR-08-3011","article-title":"Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2","volume":"15","author":"Evans","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.wneu.2017.07.036_bib19","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1001\/archneur.1994.00540140115021","article-title":"National Institutes of Health Consensus Development Conference Statement on Acoustic Neuroma, December 11-13, 1991. The Consensus Development Panel","volume":"51","year":"1994","journal-title":"Arch Neurol"},{"key":"10.1016\/j.wneu.2017.07.036_bib20","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.braindev.2013.01.007","article-title":"Characterization of early onset neurofibromatosis type 2","volume":"36","author":"Matsuo","year":"2014","journal-title":"Brain Dev"},{"key":"10.1016\/j.wneu.2017.07.036_bib21","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.1047","article-title":"A\u00a0solution to the problem of separation in logistic regression","volume":"21","author":"Heinze","year":"2002","journal-title":"Stat Med"},{"key":"10.1016\/j.wneu.2017.07.036_bib22","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajmg.1320520411","article-title":"Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity","volume":"52","author":"Parry","year":"1994","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.wneu.2017.07.036_bib23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3171\/2012.3.JNS111649","article-title":"Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors","volume":"117","author":"Dirks","year":"2012","journal-title":"J\u00a0Neurosurg"},{"key":"10.1016\/j.wneu.2017.07.036_bib24","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1097\/MAO.0b013e3181b2364c","article-title":"Concordance of bilateral vestibular schwannoma growth and hearing changes in neurofibromatosis 2: neurofibromatosis 2 Natural History Consortium","volume":"30","author":"Fisher","year":"2009","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.wneu.2017.07.036_bib25","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/00129492-200409000-00027","article-title":"Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects","volume":"25","author":"Slattery","year":"2004","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.wneu.2017.07.036_bib26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","article-title":"Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas","volume":"122","author":"Goutagny","year":"2015","journal-title":"J\u00a0Neurooncol"},{"key":"10.1016\/j.wneu.2017.07.036_bib27","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","article-title":"Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"14","author":"Karajannis","year":"2012","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2017.07.036_bib28","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/neuonc\/not150","article-title":"Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2017.07.036_bib29","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/nop010","article-title":"Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2","volume":"12","author":"Mautner","year":"2010","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.wneu.2017.07.036_bib30","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","article-title":"Hearing improvement after bevacizumab in patients with neurofibromatosis type 2","volume":"361","author":"Plotkin","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.wneu.2017.07.036_bib31","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1017\/S0022215110000460","article-title":"Use of a closed set questionnaire to measure primary and secondary effects of neurofibromatosis type 2","volume":"124","author":"Neary","year":"2010","journal-title":"J\u00a0Laryngol Otol"},{"issue":"21 Suppl 1","key":"10.1016\/j.wneu.2017.07.036_bib32","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1212\/01.wnl.0000435748.79908.c5","article-title":"Conclusions and future directions for the REiNS International Collaboration","volume":"81","author":"Widemann","year":"2013","journal-title":"Neurology"},{"issue":"7 Suppl 1","key":"10.1016\/j.wneu.2017.07.036_bib33","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1212\/WNL.0000000000002927","article-title":"Patient-reported outcomes of pain and physical functioning in neurofibromatosis clinical trials: REiNS International Collaboration","volume":"87","author":"Wolters","year":"2016","journal-title":"Neurology"}],"container-title":["World Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875017311361?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878875017311361?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T01:30:35Z","timestamp":1535592635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878875017311361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":33,"alternative-id":["S1878875017311361"],"URL":"https:\/\/doi.org\/10.1016\/j.wneu.2017.07.036","relation":{},"ISSN":["1878-8750"],"issn-type":[{"value":"1878-8750","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Population Characteristics and Progressive Disability in Neurofibromatosis Type 2","name":"articletitle","label":"Article Title"},{"value":"World Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.wneu.2017.07.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}